Yes, an adult female with a history of cholecystectomy can take tirzepatide.
Having had your gallbladder removed is not a contraindication to tirzepatide use. The primary concern with tirzepatide relates to developing new gallbladder disease in patients who still have their gallbladder, not in those who have already undergone cholecystectomy.
Key Safety Considerations
Gallbladder Disease Risk - Not Applicable After Cholecystectomy
The evidence shows tirzepatide is associated with an increased risk of gallbladder or biliary disease compared to placebo or basal insulin (RR 1.97,95% CI 1.14-3.42) 1. However, this risk primarily involves:
- Cholelithiasis (gallstones)
- Cholecystitis (gallbladder inflammation)
- Other gallbladder disorders
Since your patient no longer has a gallbladder, these specific risks are eliminated. The composite outcome that showed increased risk included gallbladder-specific complications that cannot occur post-cholecystectomy 1.
Relevant Safety Concerns That Still Apply
Even after cholecystectomy, monitor for:
Gastrointestinal effects (most common):
- Nausea, vomiting, diarrhea, decreased appetite 2, 3
- Delayed gastric emptying - this persists regardless of gallbladder status 4, 5
Metabolic complications (rare but serious):
- Starvation ketoacidosis from severe appetite suppression and inadequate caloric intake 6
- Dehydration from vomiting 7
Pancreatitis (controversial):
- Current evidence shows no statistically significant increased risk (RR 1.46,95% CI 0.59-3.61) 1
- However, case reports exist, particularly in patients with pre-existing risk factors 8
Clinical Approach
Initiate tirzepatide with standard dosing:
- Start at 2.5 mg subcutaneously weekly for 4 weeks
- Titrate to 5 mg weekly, then increase by 2.5 mg increments every 4 weeks as tolerated
- Maximum dose: 15 mg weekly 4
Early monitoring is critical - median time to adverse events is approximately 6 days 7:
- Week 1-2: Contact patient to assess tolerance, nausea, vomiting, adequate oral intake
- Monitor for signs of dehydration or ketoacidosis if intake becomes severely restricted
- Ensure adequate hydration and caloric intake despite appetite suppression
Special attention for surgical procedures:
- If future surgery is planned, discontinue tirzepatide 1 week before elective procedures due to delayed gastric emptying and aspiration risk 4, 5
- This applies to all patients on tirzepatide, regardless of gallbladder status
Bottom Line
The absence of a gallbladder actually removes one of the documented safety concerns with tirzepatide (new gallbladder disease). Focus your monitoring on gastrointestinal tolerance, adequate nutrition despite appetite suppression, and standard GLP-1 RA precautions. The medication is appropriate for this patient population.